1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition 26
3.2 Scope of the Study 26
3.3 Assumptions & Limitations 26
3.3.1 Assumptions 26
3.3.2 Limitations 26
3.4 Market Structure 27
4 Research Methodology
4.1 Research Process 29
4.2 Primary Research 30
4.3 Secondary Research 31
4.4 Market Size Estimation 31
4.5 Forecast Model 32
5 Market Dynamics
5.1 Introduction 34
5.2 Drivers 35
5.2.1 Growing Geriatric Population and Increasing Prevalence of Age–Related Macular Degeneration 35
5.2.2 Several Branded Drugs Going Off Patent 35
5.3 Restraints 36
5.3.1 High Cost Associated With AMD 36
5.3.2 Stringent FDA Regulations 36
5.4 Opportunities 36
5.4.1 Strong pipeline 36
5.5 Pipeline Analysis 37
5.5.1 Brolucizumab 6 mg 37
5.5.2 NCT01691261 37
5.5.3 NCT03102138 38
5.5.4 Lampalizumab 38
5.5.5 RG7716 38
5.5.6 Emixustat 38
5.5.7 Zimura Dry AMD 39
5.5.8 Zimura Wet AMD 39
5.5.9 GSK933776 39
5.5.10 RXI–109 39
5.5.11 Abicipar Pegol 40
6 Market Factor Analysis
6.1 Supply Chain Analysis 42
6.1.1 R&D 42
6.1.2 Parts Manufacturing 42
6.1.3 Distribution 42
6.1.4 Marketing & Sales 42
6.1.5 Post–Sales Monitoring 43
6.2 Porter’s Five Forces Analysis 43
6.2.1 Bargaining Power of Suppliers 44
6.2.2 Bargaining Power of Buyers 44
6.2.3 Threat of New Entrants 44
6.2.4 Threat of Substitutes 44
6.2.5 Intensity of Rivalry 44
7 Global Age–Related Macular Degeneration Market, by Type
7.1 Overview 46
7.1.1 Introduction 46
7.1.2 Wet Age–Related Macular Degeneration (Wet AMD) 47
7.1.3 Dry Age–Related Macular Degeneration (Dry AMD) 48
8 Global Age–Related Macular Degeneration Market, by Stages
8.1 Overview 50
8.1.1 Introduction 50
8.1.2 Intermediate Stage Age–Related Macular Degeneration 51
8.1.3 Early–Stage Age–Related Macular Degeneration 52
8.1.4 Late–Stage Age–Related Macular Degeneration 52
9 Global Age–Related Macular Degeneration Market, by Age Group
9.1 Overview 54
9.1.1 Introduction 54
9.1.2 Above 75 years 55
9.1.3 Above 60 years 55
9.1.4 Above 40 years 56
10 Global Age–Related Macular Degeneration Market, by Diagnosis & Treatment
10.1 Overview 58
10.1.1 Introduction 58
10.1.2 Treatment 59
10.1.3 Diagnosis 62
11 Global Age–Related Macular Degeneration Market, by Route of Administration
11.1 Overview 65
11.1.1 Introduction 65
11.1.2 Intravitreal Route Of Administration 66
11.1.3 Intravenous Route Of Administration 66
12 Global Age–Related Macular Degeneration Market, By End–User
12.1 Overview 69
12.1.1 Introduction 69
12.1.2 Hospital & Clinics 70
12.1.3 Diagnostic Centers 70
12.1.4 Academic Research Institutes 71
13 Age–Related Macular Degeneration Market, by Region
13.1 Introduction 73
13.2 Americas 75
13.2.1 North America 80
13.2.1.1 US. 84
13.2.1.2 Canada 89
13.2.2 South America 93
13.3 Europe 98
13.3.1 Western Europe 103
13.3.1.1 Germany 107
13.3.1.2 France 112
13.3.1.3 UK 116
13.3.1.4 Italy 120
13.3.1.5 Spain 125
13.3.1.6 Rest of Western Europe 129
13.3.2 Eastern Europe 134
13.4 Asia–Pacific 139
13.4.1 Japan 144
13.4.2 China 148
13.4.3 India 153
13.4.4 Australia 157
13.4.5 South Korea 161
13.4.6 Rest of Asia–Pacific 166
13.5 The Middle East and Africa 171
13.5.1 Middle East 176
13.5.2 Africa 180
14 Competitive Landscape
14.1 Company Market Share Analysis 186
14.1.1 Introduction 186
14.2 Key Strategic Analysis 187
14.2.1 Introduction 187
15 Company Profiles
15.1 Novartis AG 189
15.1.1 Company Overview 189
15.1.2 Financial Overview 189
15.1.3 Products Offering 190
15.1.4 Key Developments 190
15.1.5 SWOT Analysis 190
15.1.6 Key Strategy 190
15.2 Pfizer Inc. 191
15.2.1 Company Overview 191
15.2.2 Financial Overview 191
15.2.3 Products Offering 192
15.2.4 Key Developments 192
15.2.5 SWOT Analysis 192
15.2.6 Key Strategy 193
15.3 F. Hoffmann–La Roche AG 194
15.3.1 Company Overview 194
15.3.2 Financial Overview 194
15.3.3 Products Offering 195
15.3.4 Key Developments 195
15.3.5 SWOT Analysis 195
15.3.6 Key Strategy 195
15.4 Acucela Inc. 196
15.4.1 Company Overview: 196
15.4.2 Financial Overview 196
15.4.3 Products Offering 196
15.4.4 Key Developments 197
15.4.5 SWOT Analysis 197
15.4.6 Key Strategy 197
15.5 Ophthotech Corporation 198
15.5.1 Company Overview 198
15.5.2 Financial Overview 198
15.5.3 Products Offering 198
15.5.4 Key Developments 199
15.5.5 SWOT Analysis 199
15.5.6 Key Strategy 199
15.6 GlaxoSmithKline PLC 200
15.6.1 Company Overview 200
15.6.2 Financial Overview 200
15.6.3 Products Offering 201
15.6.4 Key Developments 201
15.6.5 SWOT Analysis 201
15.6.6 Key Strategy 201
15.7 Bayer AG 202
15.7.1 Company Overview 202
15.7.2 Financial Overview 202
15.7.3 Products Offering 202
15.7.4 Key Developments 203
15.7.5 SWOT Analysis 203
15.7.6 Key Strategy 203
15.8 Rxi Pharmaceuticals, Inc. 204
15.8.1 Company Overview 204
15.8.2 Financial Overview 204
15.8.3 Pipeline Products 204
15.8.4 Key Developments 204
15.8.5 SWOT Analysis 205
15.8.6 Key Strategy 205
15.9 Regeneron Pharmaceutical Inc. 206
15.9.1 Company Overview 206
15.9.2 Financial Overview 206
15.9.3 Products Offering 207
15.9.4 Key Developments 207
15.9.5 SWOT Analysis 207
15.9.6 Key Strategy 207
15.10 Alimera Sciences Inc. 208
15.10.1 Company Overview 208
15.10.2 Financial Overview 208
15.10.3 Pipeline Products 209
15.10.4 Key Developments 209
15.10.5 SWOT Analysis 209
15.10.6 Key Strategy 209
15.11 Santen Pharmaceuticals Co. 210
15.11.1 Company Overview 210
15.11.2 Financial Overview 210
15.11.3 Products Offering 211
15.11.4 SWOT Analysis 211
15.11.5 Key Developments 211
15.11.6 Key Strategy 211
15.12 ALLERGAN 212
15.12.1 Company Overview 212
15.12.2 Financial Overview 212
15.12.3 Products Offering 213
15.12.4 SWOT Analysis 213
15.12.5 Key Developments 213
15.12.6 Key Strategy 213
15.13 Bausch & Lomb Incorporated 214
15.13.1 Company Overview 214
15.13.2 Financial Overview 214
15.13.3 Products Offering 215
15.13.4 Key Developments 215
15.13.5 SWOT Analysis 215
15.13.6 Key Strategy 215
16 Appendix
16.1 Discussion Blue Print 217
17 List of Tables
TABLE 1 MARKET SYNOPSIS 24
TABLE 2 PRIMARY INTERVIEWS 29
TABLE 3 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020 & 2027 46
TABLE 4 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY TYPE, 2020–2027 (USD MILLION) 47
TABLE 5 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AGE RELATED MACULAR DEGENERATION, BY REGION, 2020–2027 (USD MILLION) 47
TABLE 6 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY REGION, 2020–2027 (USD MILLION) 48
TABLE 7 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY STAGES,, 2020–2027 (USD MILLION) 51
TABLE 8 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR INTERMEDIATE AGE–RELATED MACULAR DEGENERATION(AMD),BY REGION, 2020–2027 (USD MILLION) 51
TABLE 9 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR EARLY AGE–RELATED MACULAR DEGENERATION (AMD),BY REGION, 2020–2027 (USD MILLION) 52
TABLE 10 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY LATE AGE–RELATED MACULAR DEGENERATION (AMD),BY REGION, 2020–2027 (USD MILLION) 52
TABLE 11 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY AGE GROUP, 2020–2027 (USD MILLION) 55
TABLE 12 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR ABOVE 60 YEARS, BY REGION, 2020–2027 (USD MILLION) 56
TABLE 13 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR ABOVE 40 YEARS, BY REGION, 2020–2027 (USD MILLION) 56
TABLE 14 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 59
TABLE 15 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY REGION, 2020–2027 (USD MILLION) 60
TABLE 16 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 60
TABLE 17 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 60
TABLE 18 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 61
TABLE 19 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 61
TABLE 20 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 61
TABLE 21 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 62
TABLE 22 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY REGION, 2020–2027 (USD MILLION) 62
TABLE 23 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 63
TABLE 24 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 66
TABLE 25 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR INTRAVITREAL, BY REGION, 2020–2027 (USD MILLION) 66
TABLE 26 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR INTRAVENOUS, BY REGION, 2020–2027 (USD MILLION) 67
TABLE 27 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY END USER, 2020–2027 (USD MILLION) 70
TABLE 28 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR HOSPITAL AND CLINICS, BY REGION, 2020–2027 (USD MILLION) 70
TABLE 29 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 71
TABLE 30 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET FOR ACADEMIC RESEARCH INSTITUTES CENTERS, BY REGION, 2020–2027 (USD MILLION) 71
TABLE 31 GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2020–2027 (USD MILLION) 73
TABLE 32 AMERICAS: AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2016–2027 (USD MILLION) 75
TABLE 33 AMERICAS MARKET, BY TYPE, 2020–2027 (USD MILLION) 76
TABLE 34 AMERICAS MARKET, BY STAGES, 2020–2027 (USD MILLION) 76
TABLE 35 AMERICAS MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 76
TABLE 36 AMERICAS MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 77
TABLE 37 AMERICAS MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 77
TABLE 38 AMERICAS MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 77
TABLE 39 AMERICAS MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 78
TABLE 40 AMERICAS MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 78
TABLE 41 AMERICAS MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 78
TABLE 42 AMERICAS MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 79
TABLE 43 AMERICAS MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 79
TABLE 44 AMERICAS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 79
TABLE 45 AMERICAS MARKET, BY END USER 2020–2027 (USD MILLION) 80
TABLE 46 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 80
TABLE 47 NORTH AMERICA MARKET, BY STAGES, 2020–2027 (USD MILLION) 80
TABLE 48 NORTH AMERICA MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 81
TABLE 49 NORTH AMERICA MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 81
TABLE 50 NORTH AMERICA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 81
TABLE 51 NORTH AMERICA MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 82
TABLE 52 NORTH AMERICA MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 82
TABLE 53 NORTH AMERICA MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 82
TABLE 54 NORTH AMERICA MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 83
TABLE 55 NORTH AMERICA MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 83
TABLE 56 NORTH AMERICA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 83
TABLE 57 NORTH AMERICA MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 84
TABLE 58 NORTH AMERICA MARKET, BY END USER 2020–2027 (USD MILLION) 84
TABLE 59 US AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 60 US MARKET, BY STAGES, 2020–2027 (USD MILLION) 85
TABLE 61 US MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 85
TABLE 62 US MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 85
TABLE 63 US MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 86
TABLE 64 US MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 86
TABLE 65 US MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 86
TABLE 66 US MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 87
TABLE 67 US MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 87
TABLE 68 US MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 87
TABLE 69 US MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 88
TABLE 70 US MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 88
TABLE 71 US MARKET, BY END USER 2020–2027 (USD MILLION) 88
TABLE 72 CANADA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 89
TABLE 73 CANADA MARKET, BY STAGES, 2020–2027 (USD MILLION) 89
TABLE 74 CANADA MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 89
TABLE 75 CANADA MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 90
TABLE 76 CANADA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 90
TABLE 77 CANADA MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 90
TABLE 78 CANADA MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 91
TABLE 79 CANADA MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 91
TABLE 80 CANADA MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 91
TABLE 81 CANADA MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 92
TABLE 82 CANADA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 92
TABLE 83 CANADA MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 92
TABLE 84 CANADA MARKET, BY END USER 2020–2027 (USD MILLION) 93
TABLE 85 SOUTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 93
TABLE 86 SOUTH AMERICA MARKET, BY STAGES, 2020–2027 (USD MILLION) 93
TABLE 87 SOUTH AMERICA MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 94
TABLE 88 SOUTH AMERICA MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 94
TABLE 89 SOUTH AMERICA MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 94
TABLE 90 SOUTH AMERICA MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 95
TABLE 91 SOUTH AMERICA MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 95
TABLE 92 SOUTH AMERICA MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 95
TABLE 93 SOUTH AMERICA MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 96
TABLE 94 SOUTH AMERICA MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 96
TABLE 95 SOUTH AMERICA MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 96
TABLE 96 SOUTH AMERICA MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 97
TABLE 97 SOUTH AMERICA MARKET, BY END USER 2020–2027 (USD MILLION) 97
TABLE 98 EUROPE: AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2020–2027 (USD MILLION) 98
TABLE 99 EUROPE MARKET, BY TYPE, 2020–2027 (USD MILLION) 99
TABLE 100 EUROPE MARKET, BY STAGES, 2020–2027 (USD MILLION) 99
TABLE 101 EUROPE MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 99
TABLE 102 EUROPE MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 100
TABLE 103 EUROPE MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 100
TABLE 104 EUROPE MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 100
TABLE 105 EUROPE MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 101
TABLE 106 EUROPE MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 101
TABLE 107 EUROPE MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 101
TABLE 108 EUROPE MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 102
TABLE 109 EUROPE MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 102
TABLE 110 EUROPE MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 102
TABLE 111 EUROPE MARKET, BY END USER 2020–2027 (USD MILLION) 103
TABLE 112 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 113 WESTERN EUROPE MARKET, BY STAGES, 2020–2027 (USD MILLION) 103
TABLE 114 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 104
TABLE 115 WESTERN EUROPE MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 104
TABLE 116 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 104
TABLE 117 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 118 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 105
TABLE 119 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 105
TABLE 120 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 106
TABLE 121 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 106
TABLE 122 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 106
TABLE 123 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 107
TABLE 124 WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 107
TABLE 125 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 107
TABLE 126 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 108
TABLE 127 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 108
TABLE 128 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 108
TABLE 129 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 130 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 131 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 109
TABLE 132 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 110
TABLE 133 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 110
TABLE 134 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 110
TABLE 135 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 111
TABLE 136 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 111
TABLE 137 GERMANY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 111
TABLE 138 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 139 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 112
TABLE 140 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 112
TABLE 141 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 113
TABLE 142 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 113
TABLE 143 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 113
TABLE 144 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 114
TABLE 145 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 114
TABLE 146 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 114
TABLE 147 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 115
TABLE 148 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 115
TABLE 149 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 115
TABLE 150 FRANCE AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 116
TABLE 151 UK AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 152 UK AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 116
TABLE 153 UK AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 117
TABLE 154 UK AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 117
TABLE 155 UK AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 156 UK AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 157 UK AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 118
TABLE 158 UK AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 118
TABLE 159 UK AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 119
TABLE 160 UK AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 119
TABLE 161 UK AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 119
TABLE 162 UK AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 120
TABLE 163 UK AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 120
TABLE 164 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 165 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 121
TABLE 166 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 121
TABLE 167 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 121
TABLE 168 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 169 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 170 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 122
TABLE 171 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 123
TABLE 172 E–RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 123
TABLE 173 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 123
TABLE 174 ITALY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 124
TABLE 175 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 124
TABLE 176 ITALY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 124
TABLE 177 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 178 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 125
TABLE 179 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 125
TABLE 180 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 126
TABLE 181 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 126
TABLE 182 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 126
TABLE 183 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 127
TABLE 184 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 127
TABLE 185 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 127
TABLE 186 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 128
TABLE 187 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 128
TABLE 188 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 128
TABLE 189 SPAIN AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 129
TABLE 190 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 191 REST OF WESTERN EUROPE MARKET, BY STAGES, 2020–2027 (USD MILLION) 129
TABLE 192 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 130
TABLE 193 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 130
TABLE 194 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 195 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 196 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 131
TABLE 197 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 131
TABLE 198 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 132
TABLE 199 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 132
TABLE 200 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 132
TABLE 201 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 133
TABLE 202 REST OF WESTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 } (USD MILLION) 133
TABLE 203 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 204 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 134
TABLE 205 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 134
TABLE 206 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 135
TABLE 207 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 208 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 209 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 136
TABLE 210 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 136
TABLE 211 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 136
TABLE 212 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 137
TABLE 213 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 137
TABLE 214 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 137
TABLE 215 EASTERN EUROPE AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 138
TABLE 216 ASIA-PACIFIC: AGE-RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139
TABLE 217 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 218 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 140
TABLE 219 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 140
TABLE 220 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 141
TABLE 221 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 222 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 223 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 142
TABLE 224 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 142
TABLE 225 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 142
TABLE 226 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 143
TABLE 227 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 143
TABLE 228 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 143
TABLE 229 ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 144
TABLE 230 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 144
TABLE 231 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 144
TABLE 232 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 145
TABLE 233 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 145
TABLE 234 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 235 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 236 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 146
TABLE 237 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 146
TABLE 238 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 147
TABLE 239 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 147
TABLE 240 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 147
TABLE 241 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 148
TABLE 242 JAPAN AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 148
TABLE 243 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 244 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 149
TABLE 245 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 149
TABLE 246 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 149
TABLE 247 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 248 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 249 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 150
TABLE 250 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 151
TABLE 251 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 151
TABLE 252 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 151
TABLE 253 CHINA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 152
TABLE 254 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 152
TABLE 255 CHINA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 152
TABLE 256 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 153
TABLE 257 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 153
TABLE 258 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 153
TABLE 259 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 154
TABLE 260 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 261 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 262 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 155
TABLE 263 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 155
TABLE 264 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 155
TABLE 265 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 156
TABLE 266 INDIA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 156
TABLE 267 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 156
TABLE 268 INDIA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 157
TABLE 269 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 157
TABLE 270 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 157
TABLE 271 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 158
TABLE 272 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 158
TABLE 273 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 158
TABLE 274 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 275 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 159
TABLE 276 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 159
TABLE 277 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 160
TABLE 278 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 160
TABLE 279 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 160
TABLE 280 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 161
TABLE 281 AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 161
TABLE 282 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 283 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 162
TABLE 284 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 162
TABLE 285 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 162
TABLE 286 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 163
TABLE 287 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 163
TABLE 288 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 163
TABLE 289 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 164
TABLE 290 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 164
TABLE 291 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 164
TABLE 292 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 165
TABLE 293 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 165
TABLE 294 SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 165
TABLE 295 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 296 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020–2027 (USD MILLION) 166
TABLE 297 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 166
TABLE 298 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020–2027 (USD MILLION) 167
TABLE 299 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 167
TABLE 300 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR WET AMD TREATMENT, BY TYPE, 2020–2027 (USD MILLION) 167
TABLE 301 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTI– VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY TYPE 2020–2027 (USD MILLION) 168
TABLE 302 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY TYPE 2020–2027 (USD MILLION) 168
TABLE 303 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE 2020–2027 (USD MILLION) 168
TABLE 304 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE 2020–2027 (USD MILLION) 169
TABLE 305 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 169
TABLE 306 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 169
TABLE 307 REST OF ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER 2020–2027 (USD MILLION) 170
TABLE 308 THE MIDDLE EAST AND AFRICA: AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2020–2027 (USD MILLION) 171
TABLE 309 THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020–2027
18 List of Figures
FIGURE 1 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET: MARKET STRUCTURE 27
FIGURE 2 RESEARCH PROCESS 29
FIGURE 3 TOP–DOWN & BOTTOM–UP APPROACH 32
FIGURE 4 MARKET DYNAMICS ANALYSIS OF GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET 34
FIGURE 5 SUPPLY CHAIN: AGE–RELATED MACULAR DEGENERATION MARKET 42
FIGURE 7 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020 (% SHARE) 46
FIGURE 8 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020 (% SHARE) 50
FIGURE 9 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020 & 2027 50
FIGURE 10 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020 (% SHARE) 54
FIGURE 11 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2020 & 2027 54
FIGURE 12 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020 (% SHARE) 58
FIGURE 13 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2020 & 2027 58
FIGURE 14 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2020 (% SHARE) 65
FIGURE 15 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2020 & 2027 65
FIGURE 16 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY END USER, 2020 (% SHARE) 69
FIGURE 17 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY END USER, 2020 & 2027 69
FIGURE 18 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY REGION, 2020 & 2027 (USD MILLION) 73
FIGURE 19 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, BY REGION, 2020 (% SHARE) 74
FIGURE 20 AMERICAS: AGE–RELATED MACULAR DEGENERATION MARKET SHARE, BY REGION, 2020 (%) 75
FIGURE 21 EUROPE: AGE–RELATED MACULAR DEGENERATION MARKET SHARE, BY REGION, 2020 (%) 98
FIGURE 22 ASIA PACIFIC: AGE–RELATED MACULAR DEGENERATION MARKET SHARE, BY COUNTRY, 2020 (%) 139
FIGURE 23 THE MIDDLE EAST AND AFRICA: AGE–RELATED MACULAR DEGENERATION MARKET SHARE, BY REGION, 2020 (%) 171
FIGURE 24 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET, MARKET SHARE ANALYSIS 2020 (%) 186
FIGURE 25 GLOBAL AGE–RELATED MACULAR DEGENERATION MARKET: KEY STRATEGIC ANALYSIS 2020 (%) 187
